SCM
CCCC icon

Soleus Capital Management’s C4 Therapeutics CCCC Stock Holding History

Soleus Capital Management’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.8M Sell
3,377,981
-425,961
-11% -$1.46M 0.54% 47
2026
Q1 		$10M Hold
3,803,942
– – 0.41% 49
2025
Q4 		$7.27M Sell
3,803,942
-3,250,000
-46% -$7.7M 0.27% 58
2025
Q3 		$15.7M Buy
7,053,942
+75,000
+1% +$180K 0.79% 33
2025
Q2 		$9.98M Hold
6,978,942
– – 0.66% 39
2025
Q1 		$11.2M Hold
6,978,942
– – 0.8% 33
2024
Q4 		$25.1M Buy
6,978,942
+374,946
+6% +$1.86M 1.58% 20
2024
Q3 		$37.6M Buy
6,603,996
+2,552,000
+63% +$15.4M 2.91% 8
2024
Q2 		$18.7M Buy
4,051,996
+1,593,000
+65% +$9.5M 1.65% 21
2024
Q1 		$20.1M Buy
2,458,996
+623,000
+34% +$4.83M 1.49% 18
2023
Q4 		$10.4M Sell
1,835,996
-856,024
-32% -$1.95M 1.15% 28
2023
Q3 		$5.01M Hold
2,692,020
– – 0.46% 56
2023
Q2 		$7.4M Buy
2,692,020
+305,000
+13% +$980K 0.82% 37
2023
Q1 		$7.5M Sell
2,387,020
-53,823
-2% -$317K 0.78% 38
2022
Q4 		$14.4M Buy
2,440,843
+999,330
+69% +$8.29M 2.07% 15
2022
Q3 		$12.6M Buy
1,441,513
+1,158,873
+410% +$12M 1.72% 18
2022
Q2 		$2.13M Buy
282,640
+115,904
+70% +$1.02M 0.33% 58
2022
Q1 		$4.04M Sell
166,736
-394,386
-70% -$9.58M 0.52% 43
2021
Q4 		$18.1M Sell
561,122
-189,511
-25% -$7.49M 1.81% 21
2021
Q3 		$33.5M Sell
750,633
-120,125
-14% -$5.14M 5.23% 2
2021
Q2 		$32.9M Buy
870,758
+406,690
+88% +$14.6M 5.07% 3
2021
Q1 		$17.2M Buy
464,068
+195,520
+73% +$7.78M 3.09% 6
2020
Q4 		$8.9M Buy
+268,548
New +$7.79M 1.17% 8

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Soleus Capital Management's CCCC Position: Q2 2026 in Review

Soleus Capital Management reduced its C4 Therapeutics (CCCC) stake by 11% in Q2 2026, selling an estimated $1.46M and leaving 3,377,981 shares worth $15.8M. The position accounts for 0.54% of the portfolio, ranked #47.

Soleus Capital Management first reported a position in CCCC in Q4 2020 and has held it in 23 quarters since. The position peaked at $37.6M in Q3 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Soleus Capital Management held 3,377,981 shares of C4 Therapeutics worth $15.8M as of Q2 2026.
  • Soleus Capital Management sold 425,961 C4 Therapeutics shares in Q2 2026, an estimated $1.46M.
  • C4 Therapeutics made up 0.54% of Soleus Capital Management's portfolio in Q2 2026, its #47 holding.
  • Soleus Capital Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • Soleus Capital Management's C4 Therapeutics position peaked at $37.6M in Q3 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.